Show simple item record

dc.contributor.authorSobot, Dunja
dc.contributor.authorMura, Simona
dc.contributor.authorRouquette, Marie
dc.contributor.authorVukosavljevic, Branko
dc.contributor.authorCayre, Fanny
dc.contributor.authorBuchy, Eric
dc.contributor.authorPieters, Grégory
dc.contributor.authorGarcia-Argote, Sébastien
dc.contributor.authorWindbergs, Maike
dc.contributor.authorDesmaële, Didier
dc.contributor.authorCouvreur, Patrick
dc.date.accessioned2020-02-05T11:39:28Z
dc.date.available2020-02-05T11:39:28Z
dc.date.issued2017-07-05
dc.identifier.issn1525-0024
dc.identifier.pmid28606375
dc.identifier.doi10.1016/j.ymthe.2017.05.016
dc.identifier.urihttp://hdl.handle.net/10033/622120
dc.description.abstractSelective delivery of anticancer drugs to rapidly growing cancercells can be achieved by taking advantage of their high receptor-mediated uptake of low-density lipoproteins (LDLs). Indeed, wehave recently discovered that nanoparticles made of the squa-lene derivative of the anticancer agent gemcitabine (SQGem)strongly interacted with the LDLs in the human blood. In thepresent study, we showed both in vitro and in vivo that suchinteraction led to the preferential accumulation of SQGem incancer cells (MDA-MB-231) with high LDL receptor expression.As a result, an improved pharmacological activity has beenobserved in MDA-MB-231 tumor-bearing mice, an experi-mental model with a low sensitivity to gemcitabine. Accord-ingly, we proved that the use of squalene moieties not onlyinduced the gemcitabine insertion into lipoproteins, but thatit could also be exploited to indirectly target cancer cells in vivo.en_US
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/249835en_US
dc.rightsopenAccessen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectcanceren_US
dc.subjectgemcitabineen_US
dc.subjectindirect targetingen_US
dc.subjectlow-density lipoproteinsen_US
dc.subjectsqualene-based nanoparticlesen_US
dc.titleCirculating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.en_US
dc.typeArticleen_US
refterms.dateFOA2020-02-05T11:39:28Z
dc.source.journaltitleMolecular therapy : the journal of the American Society of Gene Therapy


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Sobot et al.pdf
Size:
1.827Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

openAccess
Except where otherwise noted, this item's license is described as openAccess